title: Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.
abstract: Fluoroquinolone (FQ) drug susceptibility testing (DST) is an important step in the design of effective treatment regimens for multidrug-resistant tuberculosis. Here we compare ciprofloxacin, ofloxacin and moxifloxacin (MFX) resistance results from 226 multidrug-resistant samples. The low level of concordance observed suggests that DST should be performed for the specific FQ planned for clinical use. The results also support the new World Health Organization recommendation for testing MFX at a critical concentration of 2.0 μg/ml.
authors: Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, USA; Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA.
authors: M R
authors: MR
authors: Farhat
authors: Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA; Department of Global Health Equity, Brigham and Women's Hospital, Boston, USA.
authors: C D
authors: CD
authors: Mitnick
authors: Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA.
authors: M F
authors: MF
authors: Franke
authors: University of Massachusetts Medical School, Massachusetts Supranational TB Reference Laboratory, Boston, USA.
authors: D
authors: D
authors: Kaur
authors: University of Massachusetts Medical School, Massachusetts Supranational TB Reference Laboratory, Boston, USA.
authors: A
authors: A
authors: Sloutsky
authors: Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA.
authors: M
authors: M
authors: Murray
authors: Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts, USA; Department of Science & Technology, National Research Foundation Centre of Excellence for Biomedical TB Research/Medical Research Council Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
authors: K R
authors: KR
authors: Jacobson
mesh_terms: D002939:Ciprofloxacin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D024841:Fluoroquinolones / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D015242:Ofloxacin / Q000494:pharmacology; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D024841:Fluoroquinolones; D002939:Ciprofloxacin; D015242:Ofloxacin; D000077266:Moxifloxacin